WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SELECT * FROM wp_clean_up_optimizer_ip_locations WHERE ip='3.238.180.174'

MCURF – Shroom Investor πŸ„

MCURF

Mind Cure Health Inc.

MINDCURE Announces Financial Results for the Third Quarter of Fiscal 2022

VANCOUVER, BC, April 26, 2022 - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE")Β today announced its financial results for the three and nine months ended February 28, 2022.Β  All amounts are stated in Canadian dollars unless otherwise indicated.Β Β  A copy of the Company's financial statements for the three and nine ... Read More...

MINDCURE Announces Strategic Review

Independent Special Committee Formed VANCOUVER, BC, Feb. 10, 2022 -Β Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology for mental health care and research in psychedelics, announced today its Board of Directors has formed a special committee (the "Special Committee") of in... Read More...

MINDCURE Hires Dr. Clare Purvis from Headspace to the position of Chief Product Officer to Advance Mental Health Digital Therapeutics Platform

VANCOUVER, BC, Feb. 3, 2022 - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology for mental health care and research in psychedelics, announced today the hiring of Dr. Clare Purvis, formerly Headspace Inc.'s Vice President of Clinical Product and Content Development, for t... Read More...

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022

VANCOUVER, BC, Jan. 25, 2022 - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research for psychedelics, today announced its financial results and operational highlights for the three and six months ended November 30, 2021.Β  All amounts are stated in Canadian dolla... Read More...

MINDCURE Joins Digital Therapeutics Alliance to Drive Innovation in the Mental Health Industry

VANCOUVER, BC, Sept. 16, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research in psychedelics, announced today it's joining the Digital Therapeutics Alliance, a non-profit association of industry leaders with a mission to drive awareness and adoption of d... Read More...

MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

MINDCURE's pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug. VANCOUVER, BC, July 27, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"), a leader in advanced proprietary technology and research for psychedelic... Read More...

MINDCURE Adopts Advance Notice Policy

VANCOUVER, BC, July 12, 2021 - Mind CureΒ Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"Β or theΒ "Company"), a leader in advanced proprietary technology and research for psychedelics,Β is pleased to announce that the Company's board of directors (the "Board") has adopted a policy that requires advance notice to the Company wit... Read More...

Maxim Group Initiates Coverage of Mind Cure Health

VANCOUVER, BC, JuneΒ 30, 2021 - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE"Β or theΒ "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that Maxim Group analysts Jason McCarthy and Michael Okunewitch initiated coverage on MINDCURE. About Mind Cure Health I... Read More...